Use Of Immunomodulatory Effective Kits For The Immunotherapeutic Treatment Of Patients Suffering From Myeloid Leukemias

A method for selecting a suitable kit for individual therapy and/or prevention of myelogenous leukemia, comprising the following steps:

• (A) ex vivo isolation of T cells from a sample of blast-containing or blast-free whole blood from the patient or stem cell donor;
• (B) subdividing the blast-containing whole blood sample of the patient into several sub-samples;
• (C) sequentially adding the following individual kits to the individual blast-containing whole blood samples at the beginning and after a first incubation period of the sub-samples, preferably 4 to 6 days, whereby leukemic blasts are converted to leukemic dendritic cells DCleu by the kits in the sub-samples:
• (i) GM-CSF, PGE2 and PICIBANIL
• (ii) GM-CSF and PICIBANIL
• (iii) GM-CSF and PGE2
• (iv) GM-CSF and PGE1
• (v) GM-CSF and TNFα
• (vi) GM-CSF and CALCIMYCIN
• (D) adding the T cells isolated in step (a) to each of the sub-samples obtained in step (c) after incubation and then incubating them during a second incubation period of preferably 7 to 10 days;
• (E) performing a lysis assay in each of the sub-samples after the incubation period in step (D) for detecting the antileukemic function of the particular kit employed;
• (F) creating a ranking for the kits used, depending on the quality of the result of the respective lysis tests;
• and
• (G) selection of the kit with the best conversion of blasts into DCleu without induction of blast proliferation and the best blast lysis result obtained after antileukemic T cell activation.